



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 10/02/2023 10:43 Received: 10/02/2023 10:43

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: ER/PR HER-2/NEU IHC Refix FISH, See Below, WMQC

Table with 4 columns: Test, Result, Flag, Ref Range. Rows include: ER/PR, PARAFFIN BLOCK IMMUNOHISTOCHEMICAL ASSAY: Paraffin Block Number, Primary Tumor Site, Quest Internal Number

RESULTS:

Table with 4 columns: Test, Result, Flag, Ref Range. Rows include: ESTROGEN RECEPTOR, ER Staining Intensity, ER Interpretation

Table with 4 columns: Test, Result, Flag, Ref Range. Rows include: PROGESTERONE RECEPTOR, PR Staining Intensity, PR Interpretation

This specimen was examined by a pathologist and showed sufficient tumor cells for testing. Positive and negative protein expression controls worked as expected.

CAP/ASCO recommends sample cold ischemia time of less than one hour with fixation in 10% neutral-buffered formalin for no less than 6 hours and no more than 72 hours, and routine processing. If the cold ischemia time, fixative, fixation time, and processing did not meet standard assay conditions, please interpret with caution and submit another specimen for retesting if possible.

This test was performed on paraffin embedded tissue sections by immunohistochemistry (HRP-linked polymer system) using monoclonal antibodies to the estrogen receptor (Leica Microsystems, clone 6F11) and the progesterone receptor (Leica Microsystems, clone 16). Interpretation was based on CAP/ASCO guidelines, which defines ER and PgR protein expression as follows:

- 1. RECEPTOR POSITIVE: at least 1% of tumor cell nuclei are immunoreactive or show positive nuclear staining of any intensity.
2. RECEPTOR NEGATIVE: less than 1% of tumor cell nuclei are immunoreactive or show staining of any intensity.
3. UNINTERPRETABLE: conditions prevent interpretation such as controls display unexpected result,

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 10/02/2023 10:43 Received: 10/02/2023 10:43

Test Name Result Flag Ref-Ranges Units Site

preanalytic/analytic conditions do not comply with
guidelines, negative result in the absence of
stained intrinsic epithelial element, and artifacts
involve most of the test sample.

The ER and PgR were scored for invasive component only
if invasive tumor or mixed invasive tumor and DCIS are
present. If no invasive tumor is present, the DCIS may
be scored for ER/PgR, see comment.

Reference:
Hammond ME, et al. American Society of Clinical
Oncology/College of American Pathologists Guideline
Recommendations for Immunohistochemical Testing of
Estrogen and Progesterone Receptors in Breast Cancer.
Arch Pathol Lab Med 2010;134:e48-72.
Results interpreted and reviewed by Lynne Lin-Chang, M.D.

ER/PR: External controls are adequate.

ER/PR Internal control tissue (i.e. benign mammary glands,
endometrium, myometrium, etc.) is present and exhibits
positive immunoreactivity.

HER2 (HercepTest-[R]), IHC
IMMUNOHISTOCHEMICAL ASSAY:
Sample fixed in Formalin? YES
Fixed between 6-48 hours? 9 HRS, 52 MINS
Routine Tissue Processing? YES
Paraffin Block Number S12-3456 A6
Primary Tumor Site LEFT BREAST BX W/ MARGINS
Quest Internal Number 2023-1234

RESULTS:
Staining Intensity 1+
HER2 Overexpression NEGATIVE
This specimen was examined by a pathologist and showed
sufficient invasive tumor cells for testing. High, low,
and negative protein expression controls worked as
expected.

CAP/ASCO recommends sample cold ischemia time of less
than one hour with fixation in 10% neutral-buffered
formalin for no less than 6 hours and no more than 72
hours, and routine processing. If the cold ischemia
time, fixative, fixation time, and processing did not
meet standard assay conditions, please interpret with

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F402000035 Ordered By: KAJAL SITWALA, MD, PhD
WX0000003827 WX00000000002365
Printed D&T: 10/02/23 10:43

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 2 OF 4



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 10/02/2023 10:43 Received: 10/02/2023 10:43

Test Name Result Flag Ref-Ranges Units Site

caution and submit another specimen for retesting if possible.

This test was performed on paraffin embedded tissue sections by immunohistochemistry using the FDA approved Dako HercepTest(TM) kit. Interpretation was based on CAP/ASCO guidelines, which defines a HER2 protein expression by immunohistochemistry as follows:

- 1. POSITIVE/IHC 3+: circumferential membrane staining that is complete, intense, observed in a homogeneous and contiguous population and within >10% of the invasive tumors and readily appreciated using a low power objective.
2. EQUIVOCAL/IHC 2+: circumferential membrane staining that is incomplete and/or weak/moderate and within >10% of the invasive tumor cells or complete and circumferential membrane staining that is intense and within < or = to 10% of the invasive tumor cells.
3. NEGATIVE/IHC 1+/0: incomplete membrane staining that is faint/barely perceptible and within >10% of the invasive tumor cells /no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within < or = to 10% of the invasive tumor cells.
4. INDETERMINATE: technical issues prevent IHC from being reported as positive, negative, or equivocal.

If an EQUIVOCAL result is obtained, a reflex HER2 FISH test will be ordered per CAP/ASCO recommendation.

Reference:
Wofff AC, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Arch Pathol Lab Med. 2013 Oct 7 Epub.
Results interpreted and reviewed by M.D.

Percentage of invasive cells with incomplete membrane staining that is faint/barely perceptible: >10%

FLUORESCENCE IN SITU HYBRID.
HER-2/neu, FISH TNP
TNP-Reflex testing not required.

TNP- WE CURRENTLY REFLEX HER2 IHC TESTING TO FISH ONLY.

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 10/02/2023 10:43 Received: 10/02/2023 10:43

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Content: FOR SPECIMENS WITH 2+ RESULTS. IHC RESULTS OF 0, 1+ OR 3+ WILL NOT BE TESTED BY THE FISH METHOD UNTIL OTHERWISE REQUESTED. PLEASE REFER TO THE RESULT OBTAINED BY IHC.

Test(s) performed at
Quest Diagnostics Nichols Institute
33608 Ortega Highway
San Juan Capistrano, CA 92675-2042
Laboratory Director: J M Nakamoto MD, PhD

Performing Site:
WMQC: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

Reported Date: 2023.10.02 10:43

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED